ArticleNeuromolecular medicine2021
Specific Susceptibility to COVID-19 in Adults with Down Syndrome.
Article in Neuromolecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Disease burden of viral respiratory infections in people with intellectual disabilities: a scoping review.BMJ open respiratory research · 2026Article
- Imagine, Discover, Inspire: Proceedings of the 4th International Conference of the Trisomy 21 Research Society.Neuromolecular medicine · 2025Article
- DYRK1A in blood and immune function: implications in leukemia, inflammatory disorders, infection and Down syndrome.Frontiers in cell and developmental biology · 2025Review
- The Impact of the COVID-19 Pandemic on Individuals with Down Syndrome: A Croatian Survey.Balkan journal of medical genetics : BJMG · 2024Article
- Tailoring remote special education for children with down syndrome during COVID-19 pandemic in the Philippines.International journal of developmental disabilities · 2024Article
- ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification.Journal of biomedical science · 2023Review
- Healthcare and Behavior Changes for Adults With Down Syndrome 1-Year Into COVID-19.American journal on intellectual and developmental disabilities · 2023Article
- DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.PLoS biology · 2023Article
- The Impact of COVID-19 Infection on Miscellaneous Inflammatory Disorders of the Gastrointestinal Tract.Gastroenterology clinics of North America · 2023Review
- Enhancing understanding of SARS-CoV-2 infection among individuals with Down syndrome: An integrative review.Sao Paulo medical journal = Revista paulista de medicina · 2023Review
- Disinfection behavior for COVID-19 in individuals with Down syndrome and caregivers' distress in Japan: a cross-sectional retrospective study.Journal of developmental and physical disabilities · 2023Article
- Will SARS-COV-2 infection accelerate the incidence of Alzheimer's disease in Down syndrome population?Aging clinical and experimental research · 2022Article
- Incidence, Hospitalization, Mortality and Risk Factors of COVID-19 in Long-Term Care Residential Homes for Patients with Chronic Mental Illness.Epidemiologia (Basel, Switzerland) · 2022Article
- Differences in clinical presentation, severity, and treatment of COVID-19 among individuals with Down syndrome from India and high-income countries: Data from the Trisomy 21 Research Society survey.Journal of global health · 2022Article
- SARS-CoV-2 vaccine humoral response in adults with Down syndrome.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- Review
- Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome.Disability and health journal · 2022Article
- Article
- Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome.Journal of clinical medicine · 2022Article
- Aging with Down Syndrome-Where Are We Now and Where Are We Going?Journal of clinical medicine · 2021Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
24 authors at 12 institutions in 7 countries.
Funding
Abstract
The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer's disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.